Our study indicates that the JAK1 and JAK2 inhibitor has stronger antifibrotic effects than the JAK3 inhibitor, and JAK2 inhibitor use also results in the loss of capillaries in BLM-induced scleroderma mice. The gene discussed is JAK3; the disease is scleroderma.